Sold out of itself: management is turning demand away today because the company cannot supply it, and the fix is already
The model's full reasoning — Q3 2018 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management describe that the company is CURRENTLY FAILING TO SERVE DEMAND IT ALREADY HAS — that real, identified buyers are being turned away, made to wait, given less than they asked for, or served later than they wanted, because the company itself cannot presently supply them — AND does management describe the company already spending or committing to remove that limit? We need to find if there is any such situation described. The transcript covers Amgen's Q3 2018 earnings call. They discuss various products: Prolia, Repatha, Aimovig, Neulasta, etc. They talk about launches, biosimilars, pipeline. The question is about a specific situation where demand is unserved due to company's own capacity constraints, and they are already acting to close the gap. Look for any mention of supply constraints, capacity issues, inability to meet demand, waiting lists, etc. For example, for Aimovig, they talk about strong launch, over 100,000 patients started, but they also mention "we've been working to resolve requests from the sizeable pent up demand" and "as we've addressed the initial bolus of patient demand we expect prescription activity to moderate and normalize." That suggests they had a bolus of demand, but they are addressing it. However, is that a failure to serve? They are serving patients, but there might be a backlog? They mention "services that we set up to assist patients in gaining early access to the product have been working to resolve requests from the sizeable pent up demand." That implies they had a queue of requests, but they are resolving them. Is that a current failure? They say "as we've addressed the initial bolus of patient demand we expect prescription activity to moderate." So they are addressing it. But is there any indication that they are turning away patients or unable to supply? They don't mention any capacity constraints on manufacturing or supply. They talk about patient access, payer approvals, etc. Not about inability to produce. For Repatha, they talk about improving access and affordability, but that's about pricing and copay, not about supply. For biosimilars, they are launching, but no mention of supply constraints. For other products, no mention of inability to meet demand.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| ZBH | Zimmer Biomet Holdings, Inc. | Q2 2017 | 2017-07-30 | F |
OGI · Q3 2022 → YESThe question is: Does management describe that the company is CURRENTLY FAILING TO SERVE DEMAND IT ALREADY HAS — real buyers being turned away, etc., because they can't supply, AND already spending or...YES The transcript shows management describing a current situation where demand is outstripping supply ("we have been really tight on our supply. Our demand was outstripping our supply"), leading to turning away or limiting sales to certain provinces ("we were really stealing from 1 pocket to the other as we're trying to balance the demand to what available capacity we had" and limiting SHRED distribution). This is material, as it affects their ability to serve existing customers fully.
CRL · Q2 2022 → YESThe question is whether management describes the company currently failing to serve demand it already has, and already spending or committing to remove that limit. YES The transcript shows clients securing space in take-or-pay arrangements because of tight capacity, indicating unserved demand from existing buyers. Management notes capacity is well utilized and they are hiring staff to accommodate higher forecasted demand, confirming they are already acting to close the gap. This situation is material given the backlog growth and emphasis on availability over price.
BRBR · Q4 2023 → YESThe question is whether management describes the company currently failing to serve demand it already has, and already spending or committing to remove that limit. NO The transcript shows ongoing capacity constraints and tight supply dynamics, with management noting they are holding back on marketing/promotions due to limited supply and that they lost customers in prior years due to capacity.